Global Vision

Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues. 

Leadership succession is proceeding within South Korean pharmaceutical corporations such as Daiichi Sankyo Korea, Astellas Pharma Korea, Kyowa Kirin Korea as well as MSD Korea.

The FDA and EMA have shared perspectives on the parallel scientific advice pilot for complex generics. Now industry stakeholders discuss whether transatlantic convergence is possible or merely a good idea on paper.

The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.

Creo Medical and Clinithink are among the healthtech innovators who have benefited from funding and advisory support offered by the Development Bank of Wales. All three gave a take on the current funding environment at BioWales in London 2024.

US-China tensions, the increasing importance of Singapore as a doorway to the Asia-Pacific region, growing AI innovation in South Korea and a changing clinical trials landscape in Japan are just some of the recent developments in APAC. 

Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.

France has long been a European leader in rare diseases, from its scientific research and academic hospitals, through to patient advocacy and regulatory reforms that have encouraged R&D. Its biotech and pharmaceutical industries are now leading the way, discovering the next generation of therapies for patients that are often overlooked.

Protein misfolding diseases, such as Alzheimer’s, are still largely untreatable and incurable. A leading scientist explains why these diseases pose unique R&D challenges and how researchers are beginning to overcome them.

Three UK medtech companies’ views on how their businesses will be influenced by external factors in the coming year.

German medtech and health care are going through a period of unprecedented change and modernization, with hospital reform on the agenda and integration of digitized functionality happening across the sector. The EU Medical Device Regulation casts a long shadow over the medtech industry and will result in a shake out among companies and products, as In Vivo learnt at Medica 2023.

Biotech founders and executives in China are embracing uncertainties as the light at the end of the tunnel is still not visible. 

The European Commission responds to questions regarding its decision to include OTC antivirals and antifungals, including commonly used products like thrush and cold sore creams, in the expanded prescription-only requirements for antimicrobials, as part of proposed measures to combat antimicrobial resistance. 

Japan has announced the latest evaluation results under its cost effectiveness assessment scheme. But how does it work and how much have prices been revised so far under the four-year-old program following discussions between pharma firms and authorities?

There is an opportunity in Austria: the country is teeming with advanced research and strong talent, but much of it remains commercially untapped. 

Biopharma executives in Israel rely on their global footprint and a 'culture of resilience'.